Purpose: This sub-analysis of the A 1 chieve study evaluated the safety and effectiveness of changing from a basal-only insulin regimen to biphasic insulin aspart 30. 
INTRODUCTION
People with type 2 diabetes who fail to attain optimal glycemic control while receiving oral glucose-lowering drugs (OGLDs) are frequently prescribed basal insulin [1] . However, there is a requirement for treatment regimens to be continually assessed, because as disease progresses it may be necessary to intensify treatment to maintain glycemic control within accepted targets [1] . One option for intensifying treatment may be to switch patients from basal insulin to premixed insulin, which contains basal plus rapid-acting insulin in one injection. There are currently few data to describe how effective premixed insulins may be in people with type 2 diabetes who are failing to maintain glycemic control on basal insulin [1] . However, meta-analyses and systematic reviews of published clinical trials indicate that premixed insulin treatment may have benefits over basal insulin treatment in enabling patients to reach glycemic targets [2, 3] .
Interventional studies have demonstrated that targeting raised post-prandial plasma glucose (PPG) hyperglycemia is essential in reducing elevated glycated hemoglobin (HbA 1c ) to accepted target levels [4] . Indeed, previous studies have demonstrated a strong correlation between elevated PPG levels and the risk of developing diabetes complications [4] [5] [6] [7] . In type 2 diabetes, basal insulins such as insulin glargine and neutral protamine Hagedorn (NPH)
insulin are effective for basal control of glucose, but do not target PPG fluctuations [8, 9] . Insulin regimens that can reduce PPG fluctuations, such as, biphasic insulin aspart 30, may be beneficial in some clinical situations, such as when basalonly insulin regimens are failing to control blood glucose levels [10] .
A 1 chieve was an international noninterventional study evaluating the safety and clinical effectiveness of insulin regimens in patients with type 2 diabetes receiving routine clinical care in 28 countries across 4 continents [11] . The full results of the A 1 chieve study have been published [11] , but it is interesting to look at specific sub-groups of this large observational study to gain information on the potential benefits of specific insulin regimens or switches to new insulin regimens. The purpose of this sub-analysis was to evaluate the safety and effectiveness of switching people with type 2 diabetes from a basal only insulin ± OGLDs regimen to a biphasic insulin aspart 30 ± OGLDs regimen. 
METHODS

RESULTS
Study Participants
A total of 2,818/66,726 (4.2%) participants were switched to biphasic insulin aspart 30 at baseline: 1,395/66,726 (2.1%; regional range 1.4%-4.2%) in the GLA group and 1,423/ 66,726 (2.1%; regional range 0.7%-7.7%) in the NEU group. Baseline patient and disease characteristics are shown in Table 1 .
Insulin and OGLD Exposure
In the GLA group, the starting mean (SD) total biphasic insulin aspart 30 dose was 0.50 (0.21) U/kg (n = 1,352) and at 24 weeks was 0.59 (0.26) U/kg (n = 1,066). In the NEU group, the starting total biphasic insulin aspart 30 dose was 0.51 (0.22) U/kg (n = 1,396) and at 24 weeks was 0.60 (0.25) U/kg (n = 1,172).
In the GLA group, most patients received twice daily biphasic insulin aspart 30 at baseline (86.0%) and after 24 weeks (82.6%). Other injection frequencies at baseline and week 24, respectively, were once daily (9.5% and 7.6%), 3 times daily (4.4% and 9.0%), and more than 3 times daily (0.1% and 0.8%). Similarly, in the NEU group, most patients received twice daily biphasic insulin aspart 30 at baseline (81.9%) and after 24 weeks (75.8%). Other injection frequencies at baseline and week 24, respectively, were once daily (9.0% and 8.7%), 3 times daily (9.0% and 14.3%) and more than 3 times daily (0.1% and 1.3%).
The most frequently prescribed OGLDs were metformin and sulfonylurea. In the GLA group 916 of 1,274 (71.9%) patients were receiving metformin before entering the study and this increased to 768 of 939 (81.8%) after 24 weeks of biphasic insulin aspart 30 treatment. In the NEU group 860 of 1,100 (78.2%) were receiving metformin before entering the study and this increased to 773 of 888 (87.0%) after 24 weeks of biphasic insulin aspart 30 treatment. In the GLA group 794 of 1,274 (62.3%) patients were receiving sulfonylurea before entering the study and this dropped to 307 of 939 (32.7%) after 24 weeks of biphasic insulin aspart 30 treatment. In the NEU group 665 of 1,100 (60.5%) patients were receiving sulfonylurea before entering the study and this dropped to 206 of 888 (23.2%) patients after 24 weeks of biphasic insulin aspart 30 treatment.
Safety Measures
Hypoglycemia After 24 weeks of receiving biphasic insulin aspart 30, the proportion of participants experiencing hypoglycemia events, major hypoglycemia, and nocturnal hypoglycemia significantly decreased from baseline in the NEU and GLA groups (p\0.05; Table 2 ). There was no indication that the proportion of patients experiencing a hypoglycemia event at baseline and at 24 weeks was higher in those taking sulfonylureas compared with those who were not taking sulfonylureas (Table 2) .
SADRs
Two SADRs were recorded that were probably due to biphasic insulin aspart 30: one hypoglycemia unconsciousness event in the GLA group and one hypoglycemia event in the NEU group.
Body Weight
There was a statistically significant (p\0.01) weight gain (0.3 kg) after 24 weeks of biphasic aspart 30 in the GLA group, but no significant weight change in the NEU group (Table 2) .
Systolic Blood Pressure
There was a statistically significant (p\0.001) reduction in systolic blood pressure after 24 weeks of biphasic aspart 30 in both the GLA group and NEU group (Table 2) .
Effectiveness Measures
Glycemic Measures
After 24 weeks of treatment with biphasic insulin aspart 30, both groups showed statistically significant improvements from baseline in HbA 1c (Fig. 1) . Specifically there was a mean 1.9% (21 mmol/mol) and 2.0% (22 mmol/mol) improvement in HbA 1c in the GLA and NEU group, respectively (Table 3) There were also significant improvements in FPG and PPG (postbreakfast, post-lunch, and post-dinner) levels (p \ 0.001; Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up GLA insulin glargine group, NEU insulin neutral protamine Hagedorn group a n = 1,381 GLA; n = 1,402 NEU b n = 1,394 GLA; n = 1,423 NEU c n = 1,352 GLA; n = 1,397 NEU d n = 1,291 GLA; n = 1,318 NEU e n = 1,368 GLA; n = 1,409 NEU f n = 1,352 GLA; n = 1,397 NEU Diabetes Ther (2013) 4:309-319 313
HRQoL
There was statistically significant (p\0.001) improvement in VAS scores after 24 weeks in both groups (Table 3) . For both groups, there was significant improvement in all five parameters of EQ-5D (no problem performing usual activities, freedom from anxiety/ depression; no problem walking; no pain or discomfort and no problems with self-care; p\0.001).
DISCUSSION
This sub-analysis from the A 1 chieve study showed that switching to therapy with biphasic insulin aspart 30 (±OGLDs) from basal insulin regimens under routine clinical Due to the non-interventional nature of this study, some patients were lost to follow-up. p calculated using McNemar's test on incidence of hypoglycemia at baseline vs. 24 weeks GLA insulin glargine group, NEU insulin neutral protamine Hagedorn group a n = 794 GLA baseline, n = 307 GLA 24 weeks; n = 665 NEU baseline, n = 206 NEU 24 weeks b n = 601 GLA baseline, n = 893 GLA 24 weeks; n = 758 NEU baseline, n = 1,065 NEU 24 weeks c n = 1,052 GLA baseline and 24 weeks; n = 1,167 NEU baseline and 24 weeks d n = 1,031 GLA baseline and 24 weeks; n = 1,140 NEU baseline and 24 weeks Importantly in both the NEU and GLA groups, improvement in glycemic control was achieved with a significant reduction in overall, major and nocturnal hypoglycemia during treatment with biphasic insulin aspart 30 (±OGLDs) relative to baseline. Despite the reduction in sulfonylurea use in both groups after 24 weeks compared with baseline, there was no indication that the proportion of patients experiencing hypoglycemia events was higher in those taking sulfonylureas compared with those not taking sulfonylureas. Therefore, the reduction in hypoglycemia events is likely to be due to the optimized treatment with biphasic insulin aspart 30. This finding would be consistent with previous studies that showed significant reductions in hypoglycemia after patients were switched from NPH insulin to biphasic insulin aspart 30 [1, 14] . Others have reported that improved Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to followup FPG fasting plasma glucose, GLA insulin glargine group, HbA1c glycated hemoglobin hemoglobin, HRQoL health-related quality of life, NEU insulin neutral protamine Hagedorn group, PPG post-prandial plasma glucose, VAS visual analogue scale hyperglycemia and a lower proportion of people experiencing hypoglycemia can be achieved and maintained in patients receiving biphasic insulin aspart 30 who have optimized their insulin dosage [15] . As there was no control arm in the study, it is not possible to determine if the placebo effect due to participation in a clinical trial had any impact on the reduced incidence of hypoglycemia.
Significant improvements in all five parameters of EQ-5D were observed in both groups after 24 weeks of biphasic insulin aspart 30. These findings are similar to those observed for the wider A 1 chieve cohort [16] , and other studies have found that treatment with biphasic insulin aspart 30 significantly improved HRQoL, improved life-expectancy, and qualityadjusted life expectancy [17] [18] [19] .
A combination of basal insulin and OGLDs is effective as an initial therapy in people with type 2 diabetes and poor glycemic control [20] .
Basal insulins, such as insulin glargine and NPH insulin, do not target PPG fluctuations [8, 9] , and, therefore, the efficacy of basal insulin begins to wane in some patients because PPG continues to rise [21] . [29] . The ADA/EASD consensus also intimates that premixed insulin may be appropriate for patients who eat regularly and who may be in need of a simplified approach to glycemic control beyond basal insulin [29] .
Regarding people with type 2 diabetes with poor glycemic control, intensification from basal insulins to biphasic premixed insulin aspart 30 may enable them to reach glycemic targets for longer periods [21] . The glycemic improvements in this analysis occurred in both groups of patients regardless of previous basal insulin regimen.
A statistically significant increase in weight was noted in the GLA group after 24 weeks of insulin aspart 30, which is in line with findings from other studies [30, 31] . However, it is questionable whether a mean 0.3 kg increase in weight after 24 weeks of insulin aspart 30 treatment is clinically important.
A limitation of the study is that it was a subanalysis of A 1 chieve with a reduction in number of participants from over 66,000 in the full study to 2,818 participants in the sub-analysis; this may have led to the risk of type II error or bias in the dataset. Also, observational studies are not randomized and are more susceptible to selection bias. For example, this sub-analysis did not control for concomitant medication or dietary intake, and some outcomes relied on self-reported information, participant recall, or diverse diaries. However, the advantage of this study is the real-world clinical setting, including actual practice patterns and a broader population than would be included in a randomized controlled trial. Furthermore, despite these limitations, data from this subanalysis will help to elucidate the safety and effectiveness of biphasic insulin aspart 30 in patients switching from basal insulin regimens. 
CONCLUSION
